BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI), an international pharmaceutical company, today announced leadership changes within its research and development (R&D) group. Effective today, Gayle R. Dolecek P.D., M.P.H., is now Executive Advisor, R&D, reflecting his change to part-time employee and new role with the Company. He will remain a member of the SPI Board of Directors.
